Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.

Phathom Pharmaceuticals Inc. submitted two new drug applications (NDAs) to the U.S. Food and Drug Administration for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) as a treatment for Helicobacter pylori infection in adults.

CytoReason and Ferring Pharmaceuticals announced a collaboration that pairs CytoReason’s artificial intelligence (AI)-based computational model of the human body with Ferring’s expertise in inflammatory bowel disease (IBD). The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.

A little more than one year after Gilead Sciences Inc. and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies pulled the plug on that goal as well as others following a Complete Response Letter issued in August 2020.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

Following a mid-stage flop, Ironwood and AbbVie discontinued the development of an experimental drug aimed at the treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

Gilead Sciences and South San Francisco-based Second Genome forged a four-year strategic collaboration worth more than $1.5 billion that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.

Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.

Oldwick, New Jersey-based Provention Bio’s PRV-6527, which was licensed from Johnson & Johnson company Janssen, failed in a mid-stage clinical trial.

Takeda Pharmaceutical Company Limited announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis, were published in The New England Journal of Medicine (NEJM).